Dr Simon Thompson and his colleagues measured urinary cotinine in 184 self reported non-smokers (May 1990; 45:356-61) . Taking 10-30% of average smokers' concentrations to indicate occasional smoking and over 30% to indicate regular smoking, they found two (1-1%) occasional smokers and no regular smokers among their non-smokers.
In an earlier study,' based on 808 self reported non-smokers, I found 11% occasional smokers and 1-4% regular smokers and, on the basis of these data and evidence from other sources on the extent to which self reported never smokers were ex-smokers, I calculated that bias caused by misclassification of smoking habits could completely explain reported excesses in lung cancer risk in non-smokers married to smokers. Thompson and colleagues argue that the lack, in their study, of typical smokers misreporting themselves as non-smokers "strongly suggests" that my hypothesis is "untenable."
Their conclusion is unreasonable for several reasons. Firstly, their study is much smaller than mine. Secondly, unlike mine it was not nationally representative, being based on men and women attending BUPA. Thirdly, the number of regular smokers observed (zero) is not different from that expected (2 6) were the underlying misclassification rate in fact 1-4%. Fourthly, they ignore evidence from several other relevant studies. Elsewhere, in a detailed review of possible health effects of environmental tobacco smoke,' I cite data from 10 studies (including Dr Thompson's and my own) of more than 100 subjects, all carried out in a context in which subjects were not actively persuaded to give up smoking (which increases misclassification rates'). Estimating the true extent of bias due to misclassification ofsmokers as non-smokers is a complex issue, made more difficult by a lack of information on rates in Oriental populations and on the extent to which current smokers misclassify themselves as lifelong never smokers (rather than as non-smokers).
An up to date review of the evidence2 underlines its importance, however, and apparently--but not actually-discrepant results from one small study can scarcely change this. AUTHORS' REPLY We commend Drs Chilvers and colleagues for finding a report that had eluded ourselves, the pharmaceutical company and recent editorials on the subject. Our report was clearly timely in reawakening interest in a therapy that had been forgotten and may be useful in carefully selected patients.
We have used vasopressin since our report was published to control profuse haemoptysis in a further patient with cystic fibrosis. Side effects were those of fluid retention that required diuretics as previously mentioned. Our case report was specific to cystic fibrosis and discussion of other serious side effects (detailed in the British National Formulary) did not seem relevant as they are well known from the use of vasopressin for oesophageal variceal bleeding in older patients.
With regard to protection ofthe airway, the patient was sucked out. It is difficult for a patient to retain a mouthpiece while coughing blood and the insertion of an endotracheal tube was contraindicated in this patient as it would have required sedation and assisted ventilation. Intravenous pressor agents resolved this problem.
The platelet count was a typographical error: it should have read 82 x 109/l; and the prothrombin measurement was a ratio [1.4] 
